Skip to main content
Fortress Biotech, Inc. logo

Fortress Biotech, Inc. — Investor Relations & Filings

Ticker · FBIO ISIN · US34960Q3074 LEI · 529900DZUWSYUURECK24 US Manufacturing
Open in API
Filings indexed 735 across all filing types
Latest filing 2026-05-14 Interim / Quarterly Rep…
Country US United States of America
Listing US FBIO

About Fortress Biotech, Inc.

https://www.fortressbiotech.com/

Fortress Biotech is an innovative biopharmaceutical company that acquires, develops, and commercializes pharmaceutical products. The company operates through a network of subsidiary and partner companies to advance a diversified portfolio. This portfolio includes revenue-generating commercial products, primarily in dermatology, and a robust pipeline of development-stage candidates. The clinical pipeline spans multiple therapeutic areas, including rare diseases, oncology, gene therapy, neurology, and pain management. Key development programs are focused on conditions such as Menkes disease, AL amyloidosis, and glioblastoma, utilizing advanced modalities like CAR-T cell therapies, oncolytic viruses, and gene therapies.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Report Publication Announcement Classification · 85% confidence The document is a Form 8-K current report filed under the Securities Exchange Act. It does not itself contain financial results but merely announces and furnishes a press release as an exhibit that contains the quarter-end results. It is not the earnings release itself (which would include actual figures) but an announcement that the report is attached. Per the “menu vs. meal” rule and the definition of Report Publication Announcement (RPA), this is an announcement of a report’s publication, so it should be classified as RPA.
2026-05-14 English
SCHEDULE 13D/A - Fortress Biotech, Inc. (0001429260) (Subject)
Major Shareholding Notification
2026-03-20 English
8-K - Fortress Biotech, Inc. (0001429260) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes details about a material definitive agreement (asset purchase agreement for a Priority Review Voucher), an amendment to a credit agreement, and other financial obligations. It also includes a press release as an exhibit. There are no comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). The document is not a transcript, proxy statement, or governance report. It is a regulatory filing reporting significant corporate events and agreements. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and detail support a high confidence level.
2026-02-23 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes an announcement of FDA approval of a drug and issuance of a Rare Pediatric Disease Priority Review Voucher, with a press release attached as an exhibit. There are no financial statements or detailed financial data presented, only a press release summary. The document length is 3474 characters, which is relatively short and consistent with an event announcement rather than a full financial report. The document is not an Annual Report, Interim Report, Earnings Release, or any detailed financial or management report. It is also not a proxy, voting result, or governance document. The best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings like Form 8-K current reports announcing significant corporate events without detailed financial data.
2026-01-13 English
SCHEDULE 13D/A Filing
Major Shareholding Notification
2026-01-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.